Introduction:
A biosimilar drug manufacturer, BioFactura, is focusing on process optimization to increase the uptake of its products in lower-income countries. By optimizing processes such as intensified profusion, CO2 stripping, and metabolomic analysis, the company aims to reduce costs and increase yields while maintaining potency and safety.
- BioFactura relies on process optimization to drive the market for biosimilars.
- Intensified perfusion and CO2 stripping techniques are used to increase yields.
- Metabolomic analysis is employed to identify supplements that improve productivity.
- Process optimization is best done after Phase I.
- Record keeping and tech transfer are crucial for successful commercial-scale production.
Conclusion:
BioFactura’s focus on process optimization has the potential to make biosimilars more accessible and affordable in lower-income countries. By reducing costs and increasing yields, biosimilars can become a viable alternative to expensive branded biologic drugs. The optimization techniques discussed by BioFactura, such as intensified perfusion and CO2 stripping, offer practical solutions for improving production efficiency. Furthermore, the utilization of metabolomic analysis can lead to the discovery of supplements that enhance productivity. These optimization strategies, combined with careful record keeping and effective tech transfer, have the potential to revolutionize the biosimilar manufacturing industry and improve access to life-saving medications.
